M
Manreet Kanwar
Cardiologist and Professor of Medicine at the University of Chicago, Director of the Heart Failure and Pulmonary Hypertension program and JHLT Deputy Editor.
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
Sep 4, 2026
Diagnosis & Management of Pulmonary Hypertension in the CICU with Dr. Manreet Kanwar
10:05
And so can you give us some insight in the factors or the information that you'd like trainees to know about management of respiratory failure with or without positive pressure?
M
10:16Manreet KanwarGUEST
So, you know, as a cardiologist, I would say the job of the lungs is just to surround the heart.
M
10:22Manreet KanwarGUEST
So triggers that can throw the RV over the edge, especially an RV that is already struggling, I think are critically important to remember.
M
10:32Manreet KanwarGUEST
So what does that mean? So let's imagine a patient has pulmonary hypertension.
M
10:36Manreet KanwarGUEST
Now they are in your ICU because something is triggering acute RV failure or acute and chronic RV failure, depending on circumstances.
13:54
One, is in treating medically hypotension, are there any pH-specific considerations that you take with regard to choice of vasopressor? And part two, is there any role for temporary mechanical circulatory support to bridge these patients through to a definitive therapy?
Episode 82: JHLT Special Issue: Device Therapies
V
8:50Van-Khue TonHOST
What is the impact of publishing in JHLT for colleagues in our field, particularly early career investigators?
M
8:58Manreet KanwarGUEST
So, you know, I, I look at Journal of Heart and Lung Transplant, of course, it's our official publication for the International Society for Heart and Lung Transplantation, and I would say that it should represent who we are and what we practice.
M
9:14Manreet KanwarGUEST
So I think of ISHLT, of course, as an international but truly a multidisciplinary society which has the unique advantage of not just focusing on the disease processes of end stage heart and lung disease but also representing, uh, you know, over 50 nations and, uh, almost 20, 25 different specialties.
M
9:36Manreet KanwarGUEST
So I think our journal is a reflection of our society, and the advantage or the impact of publishing there would be to be, um, recognized and also have a, a channel to present your science that you would present at, let's say, the International Society of Heart and Lung Transplant.
M
10:02Manreet KanwarGUEST
I started my career, my first few publications were in JHLT, and gradually I moved from, you know, uh, being a co-author to maybe the first author and then eventually the senior author, and I see that journey reflected in many, uh, colleagues and friends who've gone through the same, uh, uh, journey as well.
